title: Accelerating clinical insights: how to use accelerator mass spectrometry to make better early development decisions.
abstract: This paper is an overview of the applications of the technique of Accelerator Mass Spectrometry (AMS) in the biomedical drug development field. The work described here has been carried out at Xceleron (York, UK and Germantown, MD, USA), and it aims to apply AMS to provide better information about the human pharmacokinetic/metabolic behaviour of drugs or drug candidates as early as possible. It is hoped that the use of this technique will contribute to the delivery of better, more effective drugs onto the market sooner, which will be good news for all concerned.
authors.affiliation: Xceleron Ltd, York, UK. mark.seymour@xceleron.com
authors.forename: Mark
authors.initials: M
authors.lastname: Seymour
mesh_terms: D001682:Biological Availability; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D004345:Drug Industry; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D010315:Particle Accelerators